Evidence map›Paper›PMID 38847163›Full record

ReviewCurrent pharmaceutical biotechnology2025

Genome Editing Approaches Using Zinc Finger Nucleases (ZFNs) for the Treatment of Motor Neuron Diseases.

Medisetti Manikishore, Sandeep Kumar Maurya, Sunny Rathee, Umesh Kumar Patil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Medisetti ManikishoreDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.) 470003, India.ORCID 0009-0006-5707-7289
Sandeep Kumar MauryaDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.) 470003, India.ORCID 0000-0002-0856-5730
Sunny RatheeDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.) 470003, India.ORCID 0000-0003-2896-5982
Umesh Kumar PatilDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.) 470003, India.ORCID 0000-0002-2096-9922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motor neuron disorders encompass a spectrum of conditions that can be inherited or arise from spontaneous gene mutations. These disorders disrupt the crucial connection between motor neurons and muscles, leading to a range of symptoms, including muscle weakness, impaired coordination, and abnormal movements. Unfortunately, despite the significant impact on individuals' quality of life, there is currently no definitive cure for these disorders. In response to this pressing medical need, extensive research efforts are underway globally to develop effective treatments for motor neuron disorders. Among the emerging therapeutic strategies, gene therapy has shown considerable promise. By targeting the underlying genetic abnormalities responsible for these disorders, gene therapy aims to correct or mitigate the dysfunctional molecular pathways, offering hope for improved outcomes and potentially even disease reversal. Various approaches are being explored within the realm of gene therapy, with genetic modification techniques taking center stage. These techniques enable precise manipulation of the genetic material, facilitating the replacement of mutated genes with functional ones. One such technique that has garnered attention for its potential therapeutic efficacy is Zinc Finger Nucleases (ZFNs). ZFNs are molecular tools designed to target specific DNA sequences with high precision, enabling targeted gene editing. Their ability to induce targeted modifications in the genome holds significant promise for treating motor neuron disorders by correcting diseasecausing mutations. Moreover, ZFNs offer advantages such as accuracy and desirable therapeutic effects, making them an attractive option for gene therapy applications. Despite their potential, it is essential to acknowledge the limitations and challenges associated with ZFN-based gene therapy. These include off-target effects, delivery methods, and immune responses. Understanding and addressing these challenges are critical steps toward realizing the full therapeutic potential of ZFNs in treating motor neuron disorders. In this comprehensive review, we delve into the intricacies of ZFNs, exploring their mechanisms of action, current applications, limitations, and future prospects in gene therapy for motor neuron disorders. Additionally, we provide insights into other nucleases-mediated gene therapy approaches, highlighting their comparative advantages and challenges. Furthermore, we discuss factors influencing the efficacy and safety of gene therapy treatments, including delivery methods, immune responses, and ethical considerations. By examining these factors in detail, we aim to provide a holistic understanding of the complex landscape of gene therapy for motor neuron disorders and pave the way for future advancements in the field.

Indexed as

Gene EditingGenetic TherapyMotor Neuron DiseaseZinc Finger NucleasesAnimalsHumansZinc Finger NucleasesFOK I catalytic domain.gene delivery systemsgene therapygenome editing techniquesmotor neuron disordersZinc finger nucleases

Identifiers

PMID38847163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.